Published :
Tables : 57
Figures : 51
Category : Healthcare
No. of Pages : 245
Report Code : HC-U3327
Peptide Therapeutics Market is poised to value over USD 62 billion by 2028 end at a CAGR of over 6.4% during the forecast period 2022 to 2028. Peptides are one of the crucial therapeutic molecule classes developed by multiple biotech and pharma companies for attaining the discovery of targeted drugs for many ailments. As of now, there are over 790 peptide drugs under clinical tests and over 190 commercial peptide-based drugs are available in the market. Proteins and therapeutic peptides have proven to be primary drug candidates for over several decades. Many key players have specialised in manufacturing and developing products based on peptides from newer drug candidates to medical diagnostic devices. The soaring rise in the time span and cost of developing a traditional drug leading to the pharmaceutical companies and researchers in developing novel products that are cost-effective that are based on the strategy of synthetic peptides. Peptides have low toxicity levels due to their lower instance interaction with other molecules and due to the easy metabolism into their amino acid component residues. Pharma companies are more inclined towards peptides as they are easy to manufacture. The rising needs of peptides owing to innovative development of drugs with the bioactive properties of peptides is one of the primary interests of pharma companies. Such factors are responsible for the proliferation of the market. Major players included in the Peptide Therapeutics Market: • Eli Lilly and Company • Pfizer, Inc. • Amgen, Inc. • Takeda Pharmaceutical Company Limited • Teva Pharmaceuticals Industries Ltd. • Lonza Inc. • Sanofi • Bristol-Myers Squibb (BMS) • AstraZeneca PLC • GlaxoSmithKline plc (GSK) • Novartis AG • Novo Nordisk A/S (Note: The list of the major players will be updated with the latest market scenario and trends) Market Segmentation: By Application • Cancers • Metabolic • Cardiovascular Disorder • Respiratory • GIT • Anti-infection • Pain • Dermatology • CNS • Renal • Others By Type • Generic • Innovative By Type of Manufacturers • In-house • Outsourced By Route of Administration • Parenteral Route • Oral Route • Pulmonary • Mucosal • Others By Synthesis Technology • Solid Phase Peptide Synthesis (SPPS) • Liquid Phase Peptide Synthesis (LPPS) • Hybrid Technology By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is classified into application, type, type of manufacturers, route of administration, synthesis technology and region. The type segment is fragmented into generic and innovative drugs. The innovative peptides held the largest peptide therapeutics market share, and this can be attributed to the high rate of prescription and a rise in the number of investments by major pharma companies in developing advanced drugs. However, it is the generic segment that is predicted to experience substantial growth during the forecast period. Furthermore, patent losses to multiple branded drugs is predicted to boost the segment growth as generic players can offer low-cost options to mainstream drugs. The type of manufacturers segment is categorised into in-house and outsourced. The in-house segment is predicted to lead the market as most of the players are developing in-house peptide therapeutics due to strict regulations and high outsourcing cost. Regional Analysis: The North America region is anticipated to dominate the market, and this is primarily due to a rise in the levels of awareness related to peptide therapeutics, rising insistence for cancer diagnostics along with rising biotech industry. Furthermore, rising expenditure on research and development activities shall flourish the growth of the market. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global peptide therapeutics market - by application, by type, by type of manufacturers, by route of administration, by synthesis technology and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Peptides are one of the crucial therapeutic molecule classes developed by multiple biotech and pharma companies for attaining the discovery of targeted drugs for many ailments. As of now, there are over 790 peptide drugs under clinical tests and over 190 commercial peptide-based drugs are available in the market. Proteins and therapeutic peptides have proven to be primary drug candidates for over several decades. Many key players have specialised in manufacturing and developing products based on peptides from newer drug candidates to medical diagnostic devices. The soaring rise in the time span and cost of developing a traditional drug leading to the pharmaceutical companies and researchers in developing novel products that are cost-effective that are based on the strategy of synthetic peptides. Peptides have low toxicity levels due to their lower instance interaction with other molecules and due to the easy metabolism into their amino acid component residues. Pharma companies are more inclined towards peptides as they are easy to manufacture. The rising needs of peptides owing to innovative development of drugs with the bioactive properties of peptides is one of the primary interests of pharma companies. Such factors are responsible for the proliferation of the market.
Major players included in the Peptide Therapeutics Market: • Eli Lilly and Company • Pfizer, Inc. • Amgen, Inc. • Takeda Pharmaceutical Company Limited • Teva Pharmaceuticals Industries Ltd. • Lonza Inc. • Sanofi • Bristol-Myers Squibb (BMS) • AstraZeneca PLC • GlaxoSmithKline plc (GSK) • Novartis AG • Novo Nordisk A/S (Note: The list of the major players will be updated with the latest market scenario and trends)
Market Segmentation: By Application • Cancers • Metabolic • Cardiovascular Disorder • Respiratory • GIT • Anti-infection • Pain • Dermatology • CNS • Renal • Others
By Type • Generic • Innovative
By Type of Manufacturers • In-house • Outsourced
By Route of Administration • Parenteral Route • Oral Route • Pulmonary • Mucosal • Others
By Synthesis Technology • Solid Phase Peptide Synthesis (SPPS) • Liquid Phase Peptide Synthesis (LPPS) • Hybrid Technology
By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is classified into application, type, type of manufacturers, route of administration, synthesis technology and region. The type segment is fragmented into generic and innovative drugs. The innovative peptides held the largest peptide therapeutics market share, and this can be attributed to the high rate of prescription and a rise in the number of investments by major pharma companies in developing advanced drugs. However, it is the generic segment that is predicted to experience substantial growth during the forecast period. Furthermore, patent losses to multiple branded drugs is predicted to boost the segment growth as generic players can offer low-cost options to mainstream drugs. The type of manufacturers segment is categorised into in-house and outsourced. The in-house segment is predicted to lead the market as most of the players are developing in-house peptide therapeutics due to strict regulations and high outsourcing cost.
Regional Analysis:
The North America region is anticipated to dominate the market, and this is primarily due to a rise in the levels of awareness related to peptide therapeutics, rising insistence for cancer diagnostics along with rising biotech industry. Furthermore, rising expenditure on research and development activities shall flourish the growth of the market.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global peptide therapeutics market - by application, by type, by type of manufacturers, by route of administration, by synthesis technology and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Peptide Therapeutics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Peptide Therapeutics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Peptide Therapeutics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Peptide Therapeutics Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Cancers 7.2. Metabolic 7.3. Cardiovascular Disorder 7.4. Respiratory 7.5. GIT 7.6. Anti-infection 7.7. Pain 7.8. Dermatology 7.9. CNS 7.10. Renal 7.11. Others 8. Peptide Therapeutics Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Generic 8.2. Innovative 9. Peptide Therapeutics Market, By Type of Manufacturers Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. In-house 9.2. Outsourced 10. Peptide Therapeutics Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Parenteral Route 10.2. Oral Route 10.3. Pulmonary 10.4. Mucosal 10.5. Others 11. Peptide Therapeutics Market, By Synthesis Technology Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Solid Phase Peptide Synthesis (SPPS) 11.2. Liquid Phase Peptide Synthesis (LPPS) 11.3. Hybrid Technology 12. North America Peptide Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028 13. Latin America Peptide Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028 14. Europe Peptide Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2022-2028 15. Asia Pacific Peptide Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 16. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028 17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix 18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Eli Lilly and Company 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. Pfizer, Inc. 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. Amgen, Inc. 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Takeda Pharmaceutical Company Limited 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5. Teva Pharmaceuticals Industries Ltd. 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6. Lonza Inc. 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Sanofi 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. Bristol-Myers Squibb (BMS) 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. AstraZeneca PLC 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10. GlaxoSmithKline plc (GSK) 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11. Novartis AG 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12. Novo Nordisk A/S 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview 19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations 20. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Peptide Therapeutics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Peptide Therapeutics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Peptide Therapeutics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Peptide Therapeutics Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Cancers 7.2. Metabolic 7.3. Cardiovascular Disorder 7.4. Respiratory 7.5. GIT 7.6. Anti-infection 7.7. Pain 7.8. Dermatology 7.9. CNS 7.10. Renal 7.11. Others
8. Peptide Therapeutics Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Generic 8.2. Innovative
9. Peptide Therapeutics Market, By Type of Manufacturers Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. In-house 9.2. Outsourced
10. Peptide Therapeutics Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Parenteral Route 10.2. Oral Route 10.3. Pulmonary 10.4. Mucosal 10.5. Others
11. Peptide Therapeutics Market, By Synthesis Technology Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Solid Phase Peptide Synthesis (SPPS) 11.2. Liquid Phase Peptide Synthesis (LPPS) 11.3. Hybrid Technology
12. North America Peptide Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028
13. Latin America Peptide Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028
14. Europe Peptide Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2022-2028
15. Asia Pacific Peptide Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
16. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028
17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix
18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Eli Lilly and Company 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. Pfizer, Inc. 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. Amgen, Inc. 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Takeda Pharmaceutical Company Limited 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5. Teva Pharmaceuticals Industries Ltd. 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6. Lonza Inc. 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Sanofi 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. Bristol-Myers Squibb (BMS) 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. AstraZeneca PLC 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10. GlaxoSmithKline plc (GSK) 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11. Novartis AG 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12. Novo Nordisk A/S 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview
19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations
20. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics